Anagrelide: A New Drug for Treating Thrombocytosis

New England Journal of Medicine

Volumn 318, Issue 20, 1988, Pages 1292-1294

  Silverstein, Murray N ^a   Petitt, Robert M ^a   Solberg, Lawrence A ^a   Fleming, J Stuart ^a   Knight, Ronald C ^a   Schacter, Lee P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE;

ADULT; AGED; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTOSIS;

EID: 0023946455     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198805193182002     Document Type: Article

References (7)

1. Fleming JS, Buyniski JP. Anagrelide. In: Scriabine A, ed. New drugs annual: cardiovascular drugs. Vol. 1. New York: Raven Press, 1983:277.
2. Silverstein MN. Diagnosis and treatment of polycythemia vera, agnogenic myeloid metaplasia, and primary thrombocythemia. In: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA, eds. Neoplastic diseases of the blood. New York: Churchill-Livingstone, 1984:135.
3. Solberg LA Jr, Jamal N, Messner H. Characterization of human megakaryocytic colony formation in human plasma. J Cell Physiol 1985; 124: 67–74.
4. Silverstein MN. Essential thrombocythemia. In: Williams WJ, ed. Hematology. New York: McGraw-Hill, 1983:218.
5. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441–7.
6. Donovan PB, Kaplan ME, Goldberg JD, et al. Treatment of polycythemia vera with hydroxyurea. Am J Hematol 1984; 17: 329–34.
7. Anagrelide for platelet reduction in patients with polycythemia vera and essential thrombocythemia (protocol no. 020W1). Wallingford, Conn.: Bristol-Myers Pharmaceutical Research and Development Division, 1986.